<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14768">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261846</url>
  </required_header>
  <id_info>
    <org_study_id>3160A4-200</org_study_id>
    <secondary_id>B1871006, 3160A4-200-WW</secondary_id>
    <secondary_id>2005-004230-40</secondary_id>
    <secondary_id>B1871006</secondary_id>
    <nct_id>NCT00261846</nct_id>
  </id_info>
  <brief_title>Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias</brief_title>
  <official_title>A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, continuous daily dosing, two-part safety and efficacy study of
      SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a
      dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to
      establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun
      after the completion of Part 1 and after a dose has been established for the compound in
      chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606
      (bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL).
      The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will
      attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall
      Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will
      be evaluated as a separate cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Part 1 Baseline up to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Part 1 Baseline up to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. There were fewer participants evaluable for AUC values than participants evaluable for AUClast because terminal half-life of some participants was not accurately estimated and therefore AUC in these participants was not calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to reach maximum observed plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half-life over 24 hours at steady state (ss), on Day 15 was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUC over 24 hours at steady state (ss), on Day 15 was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent oral clearance over 24 hours at steady state (ss), on Day 15 was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio (R)</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>R=accumulation ratio (AUCss on Day 15/AUC[0-24] on Day 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Major Cytogenetic Response (MCyR) at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Population Pharmacokinetics - Part 2</measure>
    <time_frame>0 (pre-dose), 2, 4, 6 hours on Day 1, Day 21, 20-23 hours post-dose on Day 21, 0 (pre-dose) hours on Day 84, 168, 252</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Cytogenetic Response (MCyR) - Part 1</measure>
    <time_frame>Baseline, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylation Inhibition of Breakpoint Cluster Region-Abelson Kinase (Bcr-Abl) - Part 1</measure>
    <time_frame>Baseline, Week 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>bcr-Abl is a protein resulting from the transcription of the Philadelphia chromosome following 9:22 chromosomal translocation, and phosphorylation inhibition of which correlates with inhibition of tumor cell growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated Cancer-Testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Baseline - Part 1</measure>
    <time_frame>0 (pre-dose) on Day 1 (Baseline)</time_frame>
    <safety_issue>No</safety_issue>
    <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using fluorescent activated cell sorter (FACS) flow cytometry. Amount of CrkL protein phosphorylated (in moles) per 100 blood cells was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Phosphorylated Cancer-testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Day 1, 8 and 15 - Part 1</measure>
    <time_frame>6 hours post-dose on Day 1, 0 (pre-dose), 6 hours post-dose on Day 8, 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using FACS flow cytometry. Percent change in p-CrkL protein at different time points give measure of phosphorylation inhibition from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line Imatinib Intolerant CML and Chronic Phase Third-line CML Population - Part 2</measure>
    <time_frame>Week 24 for second line, Baseline through Week 24 for third line</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</measure>
    <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0% Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</measure>
    <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of MCyR was defined as the interval from the date of the earliest demonstration of a response, until the earliest date of loss of that response.
Duration of response in weeks = (date of confirmed loss of first attained response minus date of first attained response)/7 days. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</measure>
    <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to MCyR was the interval from the date of first dose of study medication until the first date of achieving a given response.
Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last cytogenetic assessment date of a participants. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Hematologic Response (CHR) - Part 2</measure>
    <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>The duration of CHR was defined as the interval from the first date of response until the first date of confirmed loss of response. Duration of response in weeks =(date of confirmed loss of first attained response - date of first attained response)/7. CHR response was considered to be achieved if participants met all of the following criteria: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;=1.0*10^9 per liter (/L), platelets &gt;=100 but &lt;450*10^9/L unless related to therapy, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Complete Hematologic Response (CHR) - Part 2</measure>
    <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to CHR was measured from the date of first dosing to the first date of response. Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last assessment date of a participant. Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Rate - Part 2</measure>
    <time_frame>Baseline up to Year 1, Year 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS was based on Kaplan-Meier estimates. PFS was defined as time in weeks from start of study treatment to treatment discontinuation due to disease progression as assessed by the investigator. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from death case report forms (CRFs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate - Part 2</measure>
    <time_frame>Baseline up to Year 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death, censored at the participant's last contact date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Hematologic Response (CHR) in Advanced Leukemia Population - Part 2</measure>
    <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>OHR included CHR, no evidence of leukemia (NEL), minor hematologic response (MiHR) or return to chronic phase (RCP), participants had to meet at least 1 of this criterion. Criteria for RCP: disappearance of features defining AP/BP, but still in CP and persistence of clonal evolution. Criteria for MiHR: &lt;15% blasts in blood and BM, &lt;30% blasts+promyelocytes in blood and BM, &lt;20% basophils in blood, no extramedullary disease other than liver/spleen. Criteria for CHR and NEL: &lt;20% basophils in blood, no extramedullary involvement including liver/spleen, no peripheral blasts or promyelocytes, myelocytes + metamyelocytes &lt;5% in blood, &lt;5% (NEL) and &lt;=5% (CHR) marrow blasts, 0.5*10^9 &lt;= Absolute neutrophil count (ANC) &lt;1.0*10^9/L (NEL) and ANC&gt;=1.0*10^9/L (CHR), 20*10^9 &lt;=platelets&lt;100 *10^9/L (NEL) and platelets&gt;=100 but &lt;450x10^9/L (CHR), white blood cells &lt;=institutional upper limit of the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Potentially Clinically Important (PCI) Adverse Events (AEs)</measure>
    <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. PCI-AEs included hepatotoxicity, gastrointestinal toxicity: diarrhea, nausea, vomiting, hypersensitivity reactions, rash, edema, effusion, myelosuppression, hemorrhage, infection, cardiac events. Duration of AE was calculated as (stop date minus start date) plus 1 for non-missing and non-partial dates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Laboratory Tests Results</measure>
    <time_frame>Week 1, 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laboratory values included urinalysis, complete blood count (CBC), prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), blood chemistry and serum pregnancy test (Î²-HCG). Potentially clinically important (PCI) changes in laboratory assessments were reported. Any laboratory value that was identified as clinically significant was reported as an AE. PCI laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline, 0 (pre-dose), 2, 4, 6 hours on Day 1, 0 (pre-dose), 2, 4, 6, 20-23 hours on Day 21, and end of treatment visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Criteria for PCI changes in ECG (12-lead) were defined as: no sinus rhythm; PR interval &gt;=220 msec and increase of &gt;=20 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) &gt;500 msec or increase of &gt;60 msec; heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Findings of Chest X-ray</measure>
    <time_frame>Baseline, Week 8, and end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Concomitant Medications for Management of Adverse Events (AEs)</measure>
    <time_frame>Baseline up to end of treatment (Year 5)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants taking any non-study medications which were administered from Study Day 1 to 30 days after last dose of study treatment as a management of an AE are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group Performance Status (ECOG-PS)</measure>
    <time_frame>Baseline, Week 1, 2, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examinations and Vital Signs</measure>
    <time_frame>Baseline up to end of treatment (Year 5)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with PCI physical examinations and vital signs is reported during therapy and at post therapy. Criteria for PCI change in vital signs: heart rate value of &lt;40 beats per minute and value &gt;150 beats per minute, systolic blood pressure (SBP) of &lt;80 or &gt;210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of &lt;40 or &gt;130 mmHg, temperature &lt;32 or &gt;40 degree centigrade, respiratory rate of &lt;10 or &gt;50 breaths/minute and criteria for PCI change in physical examination: &gt;=10% increase or decrease of body weight (Wt) in kilogram (kg).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">571</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>SKI-606</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.
Part 2, 500 mg oral, continuous, daily dosing.</description>
    <arm_group_label>SKI-606</arm_group_label>
    <other_name>SKI-606</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have
             disease progression/relapse while on full-dose imatinib, or are intolerant of any
             dose of imatinib.

          -  At least 3 months post stem cell transplantation

          -  Able to take daily oral capsules/tablets reliably

        Exclusion Criteria:

          -  Subjects with Philadelphia chromosome, and bcr-abl negative CML

          -  Overt leptomeningeal leukemia

          -  Subjects without evidence of leukemia in bone marrow (extramedullary disease only)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Faculty Associates (Gwmfa)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Service (Drug Ship)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists S.C.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St Francis Health, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Research-Franciscan St Francis Health Center Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center, Feist-Weiller Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Hematology and Oncology Associates</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Oncology Hematology Group, P.C.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital at Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center Pharmacy</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State, Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Derqui-Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de la Plata</name>
      <address>
        <city>La Plata</city>
        <state>Provincia de Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1280</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academia Nacional De Medicina</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Hematologicas</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Hematologicas</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP 1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Carlos M. Taquini</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academia Nacional de Medicina</name>
      <address>
        <city>Ciudad Autonoma de Buenos Airea</city>
        <zip>CP 1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica del Sol</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1425DQI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico S.A.</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jose Ramon Vidal</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avda. J.D. Peron 1500</name>
      <address>
        <city>Pcia de Buenos Aires</city>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital universitario austral</name>
      <address>
        <city>Pcia de Buenos Aires</city>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane And Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Care (Haematology And Oncology Clinics Of Australasia (Hoca))-Milton</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Clinics of Australia (HOCA), Mater Private Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital HAEMATOLOGY &amp; ONCOLOGY CLINICS of AUSTRALIA</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Centre For Haematology &amp; Oncology</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital - Pharmacist</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital-Hematology Clinical Trials</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Haematology Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Haematology Alfred Hospital</name>
      <address>
        <city>Melbourn</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical and Veterinary Science</name>
      <address>
        <city>Adelaide</city>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care</name>
      <address>
        <city>Milton</city>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Queensland</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology and Oncology Clinics of Australia</name>
      <address>
        <city>Queensland</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology and Oncology Clinics of Australia</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IV. Interne Abteilung</name>
      <address>
        <city>Grieskirchner</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas (HC)-Universidade Federal do Parana (UFPR)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal do Parana (HCUFPR)</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo</name>
      <address>
        <city>Jardim Paulista</city>
        <state>Sao Paulo/SP - Brazil</state>
        <zip>CEP: 01401-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP</name>
      <address>
        <city>Cerqueira Cesar</city>
        <state>Sao Paulo</state>
        <zip>05422-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo</name>
      <address>
        <city>Jardim Paulista</city>
        <state>Sao Paulo</state>
        <zip>01401901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Brigadeiro</name>
      <address>
        <city>Jardim Paulista</city>
        <state>Sao Paulo</state>
        <zip>CEP 01401-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Da Faculdade De Medicina Da</name>
      <address>
        <city>Predio Dos Ambulatorios</city>
        <state>Sao Paulo</state>
        <zip>CEP05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC - Centro de Estudos e Pesquisas de Hematologia e Oncologia</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao do ABC - FMABC / Faculdade de Medicina ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas de Hematologia e Oncologia da Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos da Disciplina de Hematologia da Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>CEP: 09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos da Disciplina de Hematologia da Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP - Bracil</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da FMUSP</name>
      <address>
        <city>Cerqueira Cesar</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>Cerqueira Cesar</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade De Medicina Do Abc</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>9060650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos da Disciplina de Hematologia da Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>CEP 09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>CEP 09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia da Faculdade de Medicina</name>
      <address>
        <city>Santo Andro</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da FMUSP - Fundacao Pro Sangue</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas - Universidade Federal do Parana</name>
      <address>
        <city>Alto da Gloria - Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da UFPR</name>
      <address>
        <city>Curitiba PR</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas - Universidade Federal do Parana</name>
      <address>
        <city>Curitiba, PR</city>
        <zip>CEP: 80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da UFPR</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas em Hematologia e Oncologia</name>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesqulsas de Heamatologia e oncologia</name>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute, Department of Medical Oncology</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba - MacCharles Unit</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre,University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Hospital - H-South Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis, Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical college Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Department of Hematology</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijing Hospital, Dept. of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, School of Medicine</name>
      <address>
        <city>Zhejiang Province</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>4459000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Santa Fe de Bogota</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedicum Helsinki -Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital (HUCH)</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedicum Helsinki - Hematology Research Unit</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedicum Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital (HUCH)</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>Fin-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <state>RP</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Carl Gustav Carus, der Technischen Universitat Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus an der Technischen UniversitÃ¤t Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Magdeburg A. oe. R.</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Gutenberg Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Mainz Iii. Medizinische Klinik Abteilung Fuer Haematologie</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Mannheim, CML-Studienzentrale</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hosp.</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz / Haematologia es Ossejt-Transzplantacios osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan and St. Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <state>Province of Bologna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant' Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Hematology</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Estatal ISSEMYM</name>
      <address>
        <city>Toluca</city>
        <state>Estado de Mexico</state>
        <zip>CP 50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>064460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De Nuevo Leon</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UANL</name>
      <address>
        <city>Neuvo Leon</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Nuevo Leon</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Estatal Issemym</name>
      <address>
        <city>Toluca, Estado De Mexico</city>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Estatal Issemym</name>
      <address>
        <city>Toluca</city>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEC</name>
      <address>
        <city>Groningem</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG - Pharmacy</name>
      <address>
        <city>Groningen</city>
        <zip>9713 AP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>The Netherlands</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avd. for blodsykdommer</name>
      <address>
        <city>Trondheim</city>
        <state>Norge</state>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Edgardo Rebagliati Martins</name>
      <address>
        <city>Jesus Maria</city>
        <state>Lima - Peru</state>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edgardo Rebegliati Martins National Hospital</name>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Edgardo Rebagliati Martins</name>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital N 31</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>St. Peterburg</state>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution, Sverdlovsk Regional Clinical Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Clinic</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blodd transfusion of Roszdrav - Hematology Clinic</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute Of Hematology And Blood Transfusion Of Rosmedtechnology</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution Hematology Scientific Center of Minzdravsotsrazvitiya of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematological Research Centre of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow regional Clinical Research Institute named after M.F Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University of Roszdrav</name>
      <address>
        <city>Rostov-on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academician IPPavlov St. Petersburg state medical university</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Petersburg Pavlov's State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital, Department of Haematology</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Donald Gordon Clinical Trial Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research, Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand Oncology, Donald Gordon Medical Centre</name>
      <address>
        <city>Parktown</city>
        <state>Johannesburg</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Donald Gordon Clinical Trial Site</name>
      <address>
        <city>Parktown</city>
        <state>Johannesburg</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Free State</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Free State</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology and Cell Biology</name>
      <address>
        <city>Bloemfontein</city>
        <zip>ZA-9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Haematology</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannesburg Hospital</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Witwatersrand Oncology</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Witwatersrand Oncology-Johannesburg Hospital</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Witwatersrand Oncology</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Donald Gordon Clinical Trial Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Haematology Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WCR: Wits Clinical Research</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona (Hospital Clinic i Provincial)</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia (CHUV)</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital - Section of Hematology-Oncology</name>
      <address>
        <city>Taipei 100</city>
        <zip>10018</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>North East England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals - NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>North East England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Clinical and Laboratory Sciences</name>
      <address>
        <city>University upon Tyne</city>
        <state>North East England</state>
        <zip>NE1 7RU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London Hammersmith Hospital-Catherine Lewis Centre</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary - Clinical Research Facility</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary-The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital, Nothern Centre for Cancer Care</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nothern Centre for Cancer Care Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University - School of Clinical and Laboratory Sciences</name>
      <address>
        <city>Newcastle</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, University of Newcastle</name>
      <address>
        <city>North East England</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Newcastle - Royal Victoria Infirmary</name>
      <address>
        <city>North East England</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University School of Clinical and Laboratory Sciences</name>
      <address>
        <city>North East England</city>
        <zip>NE1 7RU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital Northern Centre for Cancer Care</name>
      <address>
        <city>North East England</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3160A4-200&amp;StudyName=Study%20Evaluating%20SKI-606%20%28Bosutinib%29%20In%20Philadelphia%20Chromosome%20Positive%20Leukemias</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 27, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2005</firstreceived_date>
  <firstreceived_results_date>October 4, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>philadelphia chromosome</keyword>
  <keyword>Myeloid</keyword>
  <keyword>Philadelphia Positive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abnormal Karyotype</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bosutinib 400 mg (Part 1)</title>
          <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Bosutinib 500 mg (Part 1)</title>
          <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
        </group>
        <group group_id="P3">
          <title>Bosutinib 600 mg (Part 1)</title>
          <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. Eleven participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
        </group>
        <group group_id="P4">
          <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P5">
          <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P6">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P7">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P8">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P9">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P10">
          <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P11">
          <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P12">
          <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P13">
          <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="P14">
          <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1: Dose-escalation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Continued in to Part 2: Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2: Efficacy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="200">17 participants from Part 1 (Bosutinib 400mg, 500mg, 600mg cohort) continued in Part 2 of the study.</participants>
                <participants group_id="P5" count="88"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="27"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="46">1 participant from Part 1 (Bosutinib 600mg cohort) continued in Part 2 of the study.</participants>
                <participants group_id="P11" count="31"/>
                <participants group_id="P12" count="35"/>
                <participants group_id="P13" count="29"/>
                <participants group_id="P14" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="162"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="33"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="42"/>
                <participants group_id="P11" count="25"/>
                <participants group_id="P12" count="26"/>
                <participants group_id="P13" count="26"/>
                <participants group_id="P14" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Active on treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="92"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Active on long term follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="23"/>
                <participants group_id="P14" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B2">
          <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B3">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B4">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B5">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B6">
          <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B7">
          <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B8">
          <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B9">
          <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B10">
          <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B11">
          <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
          <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="200"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="37"/>
                <measurement group_id="B4" value="50"/>
                <measurement group_id="B5" value="27"/>
                <measurement group_id="B6" value="4"/>
                <measurement group_id="B7" value="45"/>
                <measurement group_id="B8" value="31"/>
                <measurement group_id="B9" value="35"/>
                <measurement group_id="B10" value="29"/>
                <measurement group_id="B11" value="24"/>
                <measurement group_id="B12" value="570"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Less than 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="163"/>
                <measurement group_id="B2" value="61"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="34"/>
                <measurement group_id="B5" value="25"/>
                <measurement group_id="B6" value="4"/>
                <measurement group_id="B7" value="42"/>
                <measurement group_id="B8" value="26"/>
                <measurement group_id="B9" value="32"/>
                <measurement group_id="B10" value="21"/>
                <measurement group_id="B11" value="13"/>
                <measurement group_id="B12" value="451"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Greater than or equal to 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="16"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="3"/>
                <measurement group_id="B8" value="5"/>
                <measurement group_id="B9" value="3"/>
                <measurement group_id="B10" value="8"/>
                <measurement group_id="B11" value="11"/>
                <measurement group_id="B12" value="119"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="23"/>
                <measurement group_id="B4" value="27"/>
                <measurement group_id="B5" value="13"/>
                <measurement group_id="B6" value="2"/>
                <measurement group_id="B7" value="21"/>
                <measurement group_id="B8" value="13"/>
                <measurement group_id="B9" value="11"/>
                <measurement group_id="B10" value="12"/>
                <measurement group_id="B11" value="12"/>
                <measurement group_id="B12" value="269"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="116"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="23"/>
                <measurement group_id="B5" value="14"/>
                <measurement group_id="B6" value="2"/>
                <measurement group_id="B7" value="24"/>
                <measurement group_id="B8" value="18"/>
                <measurement group_id="B9" value="24"/>
                <measurement group_id="B10" value="17"/>
                <measurement group_id="B11" value="12"/>
                <measurement group_id="B12" value="301"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicity (DLT)</title>
        <description>DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
        <time_frame>Part 1 Baseline up to Day 28</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Dose Limiting Toxicity (DLT)</title>
            <description>DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
        <time_frame>Part 1 Baseline up to Day 28</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
            <description>All participants who received single oral dose of bosutinib 400 mg, 500 mg or 600 mg on Day 1 and then bosutinib 400 mg, 500 mg or 600 mg orally once daily continuously from Day 3 up to Week 4.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).</description>
            <units>mg</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">MTD was not achieved since no more than 1 DLT was observed in any cohort. At the 600mg dose level, 1 DLT and several treatment related grade 2 toxicities were observed, thus, Bosutinib 500 mg was selected as the recommended dose for part 2.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) - Part 1</title>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Plasma Concentration (Cmax) - Part 1</title>
            <units>nanogram per milliliter (ng/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89.3" spread="50.0"/>
                  <measurement group_id="O2" value="101.0" spread="35.6"/>
                  <measurement group_id="O3" value="120.0" spread="40.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1</title>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1</title>
            <units>hours (hrs)</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.00" lower_limit="3.33" upper_limit="48.08"/>
                  <measurement group_id="O2" value="6.00" lower_limit="6.00" upper_limit="6.00"/>
                  <measurement group_id="O3" value="4.00" lower_limit="2.17" upper_limit="49.33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2) - Part 1</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Decay Half-Life (t1/2) - Part 1</title>
            <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
            <units>hrs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.91">Standard deviation obtained by sampling distribution of 2 participants was not meaningful, hence not reported.</measurement>
                  <measurement group_id="O2" value="22.46" spread="1.73"/>
                  <measurement group_id="O3" value="22.24" spread="5.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) - Part 1</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) - Part 1</title>
            <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
            <units>ng*hr/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1850" spread="710"/>
                  <measurement group_id="O2" value="2060" spread="483"/>
                  <measurement group_id="O3" value="2340" spread="1140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve (AUC) - Part 1</title>
        <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. There were fewer participants evaluable for AUC values than participants evaluable for AUClast because terminal half-life of some participants was not accurately estimated and therefore AUC in these participants was not calculated.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Concentration-Time Curve (AUC) - Part 1</title>
            <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. There were fewer participants evaluable for AUC values than participants evaluable for AUClast because terminal half-life of some participants was not accurately estimated and therefore AUC in these participants was not calculated.</description>
            <units>ng*hr/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2530">Standard deviation obtained by sampling distribution of 2 participants was not meaningful, hence not reported.</measurement>
                  <measurement group_id="O2" value="2760" spread="687"/>
                  <measurement group_id="O3" value="2420" spread="457"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) - Part 1</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Oral Clearance (CL/F) - Part 1</title>
            <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
            <units>liter per hour (L/hr)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177">Standard deviation obtained by sampling distribution of 2 participants was not meaningful, hence not reported.</measurement>
                  <measurement group_id="O2" value="189" spread="47.5"/>
                  <measurement group_id="O3" value="258" spread="61.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) - Part 1</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Volume of Distribution (Vz/F) - Part 1</title>
            <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
            <units>liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6050" spread="3550"/>
                  <measurement group_id="O2" value="6080" spread="1230"/>
                  <measurement group_id="O3" value="8540" spread="3820"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1</title>
        <description>Maximum plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1</title>
            <description>Maximum plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="146" spread="20.0"/>
                  <measurement group_id="O2" value="200" spread="11.9"/>
                  <measurement group_id="O3" value="208" spread="73.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1</title>
        <description>Time to reach maximum observed plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1</title>
            <description>Time to reach maximum observed plasma concentration over 24 hours at steady state (ss), on Day 15.</description>
            <units>hrs</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.05" lower_limit="3.08" upper_limit="6.08"/>
                  <measurement group_id="O2" value="6.05" lower_limit="4.00" upper_limit="8.00"/>
                  <measurement group_id="O3" value="6.00" lower_limit="2.83" upper_limit="11.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half-life over 24 hours at steady state (ss), on Day 15 was calculated.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1</title>
            <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half-life over 24 hours at steady state (ss), on Day 15 was calculated.</description>
            <units>hrs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45.96" spread="32.30"/>
                  <measurement group_id="O2" value="21.71" spread="4.64"/>
                  <measurement group_id="O3" value="25.87" spread="24.85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1</title>
        <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUC over 24 hours at steady state (ss), on Day 15 was calculated.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1</title>
            <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUC over 24 hours at steady state (ss), on Day 15 was calculated.</description>
            <units>ng*hr/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2720" spread="442"/>
                  <measurement group_id="O2" value="3650" spread="425"/>
                  <measurement group_id="O3" value="3630" spread="1270"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent oral clearance over 24 hours at steady state (ss), on Day 15 was calculated.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1</title>
            <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent oral clearance over 24 hours at steady state (ss), on Day 15 was calculated.</description>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="150" spread="23.2"/>
                  <measurement group_id="O2" value="138" spread="16.6"/>
                  <measurement group_id="O3" value="185" spread="66.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio (R)</title>
        <description>R=accumulation ratio (AUCss on Day 15/AUC[0-24] on Day 1)</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Accumulation Ratio (R)</title>
            <description>R=accumulation ratio (AUCss on Day 15/AUC[0-24] on Day 1)</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.1" spread="1.4"/>
                  <measurement group_id="O2" value="2.8" spread="0.8"/>
                  <measurement group_id="O3" value="2.5" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Major Cytogenetic Response (MCyR) at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2</title>
        <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Major Cytogenetic Response (MCyR) at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2</title>
            <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35.5" lower_limit="29.7" upper_limit="41.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Population Pharmacokinetics - Part 2</title>
        <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
        <time_frame>0 (pre-dose), 2, 4, 6 hours on Day 1, Day 21, 20-23 hours post-dose on Day 21, 0 (pre-dose) hours on Day 84, 168, 252</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Cytogenetic Response (MCyR) - Part 1</title>
        <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
        <time_frame>Baseline, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Cytogenetic evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline cytogenetic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Major Cytogenetic Response (MCyR) - Part 1</title>
            <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells and PCyR was achieved when 1 to 35% Ph+ cells.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  <measurement group_id="O2" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  <measurement group_id="O3" value="50.0" lower_limit="21.1" upper_limit="78.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylation Inhibition of Breakpoint Cluster Region-Abelson Kinase (Bcr-Abl) - Part 1</title>
        <description>bcr-Abl is a protein resulting from the transcription of the Philadelphia chromosome following 9:22 chromosomal translocation, and phosphorylation inhibition of which correlates with inhibition of tumor cell growth.</description>
        <time_frame>Baseline, Week 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data was not summarized since inadequate data included the issue that molecular transcript analyses could not be performed, because of potential sample quality issues due to time required to transport the specimens from the few investigational sites to the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phosphorylation Inhibition of Breakpoint Cluster Region-Abelson Kinase (Bcr-Abl) - Part 1</title>
            <description>bcr-Abl is a protein resulting from the transcription of the Philadelphia chromosome following 9:22 chromosomal translocation, and phosphorylation inhibition of which correlates with inhibition of tumor cell growth.</description>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylated Cancer-Testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Baseline â Part 1</title>
        <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using fluorescent activated cell sorter (FACS) flow cytometry. Amount of CrkL protein phosphorylated (in moles) per 100 blood cells was reported.</description>
        <time_frame>0 (pre-dose) on Day 1 (Baseline)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phosphorylated Cancer-Testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Baseline â Part 1</title>
            <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using fluorescent activated cell sorter (FACS) flow cytometry. Amount of CrkL protein phosphorylated (in moles) per 100 blood cells was reported.</description>
            <units>moles/100 blood cells</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="457075" spread="559841.90"/>
                  <measurement group_id="O2" value="297967.33" spread="171643.30"/>
                  <measurement group_id="O3" value="397795.40" spread="552536.90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Phosphorylated Cancer-testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Day 1, 8 and 15 - Part 1</title>
        <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using FACS flow cytometry. Percent change in p-CrkL protein at different time points give measure of phosphorylation inhibition from baseline.</description>
        <time_frame>6 hours post-dose on Day 1, 0 (pre-dose), 6 hours post-dose on Day 8, 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' signifies number of participants who were evaluable for this measure. n=number of participants evaluable for this measure at specified time points for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 400 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 600 mg (Part 1)</title>
            <description>Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line chronic myelogenous leukemia (CP2L-CML) Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase chronic myelogenous leukemia (AP-CML) Part 2 of the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Phosphorylated Cancer-testis 10 (CT10) Regulator of Kinase Like (p-CrkL) Protein Level in Blood at Day 1, 8 and 15 - Part 1</title>
            <description>CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells by using FACS flow cytometry. Percent change in p-CrkL protein at different time points give measure of phosphorylation inhibition from baseline.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1: post-dose (n=1, 1, 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-34.66">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O2" value="287.52">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O3" value="97.79" spread="283.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 8: pre-dose (n=1, 1, 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="562.48">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O2" value="170.83">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O3" value="3.88" spread="128.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 8: post-dose (n=1, 1, 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="528.62">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O2" value="429.79">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O3" value="143.57" spread="289.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 15: pre-dose (n=1, 2, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177.87">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O2" value="-44.64" spread="8.56"/>
                  <measurement group_id="O3" value="119.23" spread="170.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 15: post-dose (n=1, 3, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-49.85">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  <measurement group_id="O2" value="-21.13" spread="57.91"/>
                  <measurement group_id="O3" value="138.45" spread="278.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line Imatinib Intolerant CML and Chronic Phase Third-line CML Population - Part 2</title>
        <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
        <time_frame>Week 24 for second line, Baseline through Week 24 for third line</time_frame>
        <safety_issue>No</safety_issue>
        <population>Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="43"/>
                  <measurement group_id="O4" value="26"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line Imatinib Intolerant CML and Chronic Phase Third-line CML Population - Part 2</title>
            <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30.0" lower_limit="21.6" upper_limit="39.5"/>
                  <measurement group_id="O2" value="25.7" lower_limit="14.1" upper_limit="40.6"/>
                  <measurement group_id="O3" value="25.6" lower_limit="15.1" upper_limit="38.8"/>
                  <measurement group_id="O4" value="26.9" lower_limit="13.4" upper_limit="44.7"/>
                  <measurement group_id="O5" value="50.0" lower_limit="9.8" upper_limit="90.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
        <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0% Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
        <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="43"/>
                  <measurement group_id="O5" value="26"/>
                  <measurement group_id="O6" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
            <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from Bone Marrow (BM) sample. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0% Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55.4" lower_limit="47.9" upper_limit="62.7"/>
                  <measurement group_id="O2" value="48.8" lower_limit="37.4" upper_limit="60.2"/>
                  <measurement group_id="O3" value="31.4" lower_limit="16.9" upper_limit="49.3"/>
                  <measurement group_id="O4" value="30.2" lower_limit="17.2" upper_limit="46.1"/>
                  <measurement group_id="O5" value="34.6" lower_limit="17.2" upper_limit="55.7"/>
                  <measurement group_id="O6" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
        <description>Duration of MCyR was defined as the interval from the date of the earliest demonstration of a response, until the earliest date of loss of that response.
Duration of response in weeks = (date of confirmed loss of first attained response minus date of first attained response)/7 days. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
        <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subgroup of participants from evaluable population who had confirmed major cytogenic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="9"/>
                  <measurement group_id="O6" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
            <description>Duration of MCyR was defined as the interval from the date of the earliest demonstration of a response, until the earliest date of loss of that response.
Duration of response in weeks = (date of confirmed loss of first attained response minus date of first attained response)/7 days. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Median duration of MCyR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O2" value="NA">Median duration of MCyR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O3" value="24.1" lower_limit="18.0">Upper limit of the 95% CI was not estimable because not enough participants had lost MCyR and the Kaplan-Meier curve had not dropped enough.</measurement>
                  <measurement group_id="O4" value="NA">Median duration of MCyR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O5" value="NA">Median duration of MCyR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O6" value="NA">Median was not estimable since sample size was too small to suggest accurate estimates.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
        <description>Time to MCyR was the interval from the date of first dose of study medication until the first date of achieving a given response.
Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last cytogenetic assessment date of a participants. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
        <time_frame>Baseline, Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="43"/>
                  <measurement group_id="O5" value="26"/>
                  <measurement group_id="O6" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML and Chronic Phase Third-line CML - Part 2</title>
            <description>Time to MCyR was the interval from the date of first dose of study medication until the first date of achieving a given response.
Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last cytogenetic assessment date of a participants. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells in metaphase in BM and PCyR was achieved when 1 to 35% Ph+ cells in metaphase in BM.</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36.0" lower_limit="24.1" upper_limit="49.0"/>
                  <measurement group_id="O2" value="24.4" lower_limit="12.3" upper_limit="48.0"/>
                  <measurement group_id="O3" value="88.4" lower_limit="22.3">Upper limit of the 95% CI was not estimable because not enough participants had achieved MCyR and the Kaplan-Meier curve had not risen enough.</measurement>
                  <measurement group_id="O4" value="NA" lower_limit="24.0">Median time to MCyR has not been reached since the Kaplan-Meier curve has not risen above 50%.</measurement>
                  <measurement group_id="O5" value="NA" lower_limit="24.1">Median time to MCyR has not been reached since the Kaplan-Meier curve has not risen above 50%.</measurement>
                  <measurement group_id="O6" value="24.0" lower_limit="12.0" upper_limit="24.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Complete Hematologic Response (CHR) - Part 2</title>
        <description>The duration of CHR was defined as the interval from the first date of response until the first date of confirmed loss of response. Duration of response in weeks =(date of confirmed loss of first attained response - date of first attained response)/7. CHR response was considered to be achieved if participants met all of the following criteria: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;=1.0*10^9 per liter (/L), platelets &gt;=100 but &lt;450*10^9/L unless related to therapy, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
        <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subgroup of participants from evaluable population who had confirmed complete hematologic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="170"/>
                  <measurement group_id="O2" value="74"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="39"/>
                  <measurement group_id="O5" value="20"/>
                  <measurement group_id="O6" value="3"/>
                  <measurement group_id="O7" value="16"/>
                  <measurement group_id="O8" value="8"/>
                  <measurement group_id="O9" value="8"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Complete Hematologic Response (CHR) - Part 2</title>
            <description>The duration of CHR was defined as the interval from the first date of response until the first date of confirmed loss of response. Duration of response in weeks =(date of confirmed loss of first attained response - date of first attained response)/7. CHR response was considered to be achieved if participants met all of the following criteria: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;=1.0*10^9 per liter (/L), platelets &gt;=100 but &lt;450*10^9/L unless related to therapy, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O2" value="NA">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O3" value="NA" lower_limit="27.1">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O4" value="NA">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O5" value="108.0" lower_limit="56.0">Upper limit of the 95% CI was not estimable because not enough participants had lost CHR and the Kaplan-Meier curve had not dropped enough.</measurement>
                  <measurement group_id="O6" value="NA">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O7" value="138.0" lower_limit="33.0">Upper limit of the 95% CI was not estimable because not enough participants had lost CHR and the Kaplan-Meier curve had not dropped enough.</measurement>
                  <measurement group_id="O8" value="NA" lower_limit="102.0">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                  <measurement group_id="O9" value="28.0" lower_limit="20.1" upper_limit="32.0"/>
                  <measurement group_id="O10" value="40.0">Upper and lower limit of the 95% CI was not estimable because not enough participants had lost CHR and the Kaplan-Meier curve had not dropped enough.</measurement>
                  <measurement group_id="O11" value="NA" lower_limit="10.0">Median duration of CHR has not been reached since the Kaplan-Meier curve has not dropped below 50%.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Complete Hematologic Response (CHR) - Part 2</title>
        <description>The time to CHR was measured from the date of first dosing to the first date of response. Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last assessment date of a participant. Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
        <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Hematologic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline hematologic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="49"/>
                  <measurement group_id="O5" value="26"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="39"/>
                  <measurement group_id="O8" value="30"/>
                  <measurement group_id="O9" value="33"/>
                  <measurement group_id="O10" value="27"/>
                  <measurement group_id="O11" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Achieve Complete Hematologic Response (CHR) - Part 2</title>
            <description>The time to CHR was measured from the date of first dosing to the first date of response. Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response or last assessment date of a participant. Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="2.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.1" lower_limit="1.3" upper_limit="3.0"/>
                  <measurement group_id="O3" value="3.1" lower_limit="2.3">Upper limit of the 95% CI was not estimable because not enough participants had achieved CHR and the Kaplan-Meier curve had not risen enough.</measurement>
                  <measurement group_id="O4" value="2.1" lower_limit="1.1" upper_limit="3.1"/>
                  <measurement group_id="O5" value="3.1" lower_limit="2.0" upper_limit="4.1"/>
                  <measurement group_id="O6" value="2.1" lower_limit="1.1">Upper limit of the 95% CI was not estimable because not enough participants had achieved CHR and the Kaplan-Meier curve had not risen enough.</measurement>
                  <measurement group_id="O7" value="36.1" lower_limit="12.1">Upper limit of the 95% CI was not estimable because not enough participants had achieved CHR and the Kaplan-Meier curve had not risen enough.</measurement>
                  <measurement group_id="O8" value="50.0" lower_limit="36.0">Upper limit of the 95% CI was not estimable because not enough participants had achieved CHR and the Kaplan-Meier curve had not risen enough.</measurement>
                  <measurement group_id="O9" value="NA" lower_limit="13.0">Median time to CHR has not been reached since the Kaplan-Meier curve has not risen above 50%.</measurement>
                  <measurement group_id="O10" value="NA">Median time to CHR has not been reached since the Kaplan-Meier curve has not risen above 50%.</measurement>
                  <measurement group_id="O11" value="83.1">Upper and lower limit of the 95% CI was not estimable because not enough participants had achieved CHR and the Kaplan-Meier curve had not risen enough.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) Rate - Part 2</title>
        <description>PFS was based on Kaplan-Meier estimates. PFS was defined as time in weeks from start of study treatment to treatment discontinuation due to disease progression as assessed by the investigator. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from death case report forms (CRFs).</description>
        <time_frame>Baseline up to Year 1, Year 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>All-treated population included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="45"/>
                  <measurement group_id="O8" value="31"/>
                  <measurement group_id="O9" value="35"/>
                  <measurement group_id="O10" value="29"/>
                  <measurement group_id="O11" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival (PFS) Rate - Part 2</title>
            <description>PFS was based on Kaplan-Meier estimates. PFS was defined as time in weeks from start of study treatment to treatment discontinuation due to disease progression as assessed by the investigator. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from death case report forms (CRFs).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Year 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89.9" lower_limit="84.2" upper_limit="93.6"/>
                  <measurement group_id="O2" value="95.1" lower_limit="85.5" upper_limit="98.4"/>
                  <measurement group_id="O3" value="64.7" lower_limit="41.7" upper_limit="80.5"/>
                  <measurement group_id="O4" value="80.5" lower_limit="62.8" upper_limit="90.4"/>
                  <measurement group_id="O5" value="84.5" lower_limit="63.8" upper_limit="93.9"/>
                  <measurement group_id="O6" value="NA">The sample size was too small to suggest accurate estimates.</measurement>
                  <measurement group_id="O7" value="63.2" lower_limit="46.4" upper_limit="76.0"/>
                  <measurement group_id="O8" value="68.7" lower_limit="46.3" upper_limit="83.3"/>
                  <measurement group_id="O9" value="13.2" lower_limit="3.4" upper_limit="29.9"/>
                  <measurement group_id="O10" value="15.3" lower_limit="4.1" upper_limit="33.2"/>
                  <measurement group_id="O11" value="6.0" lower_limit="0.4" upper_limit="23.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.2" lower_limit="68.4" upper_limit="82.3"/>
                  <measurement group_id="O2" value="92.8" lower_limit="81.6" upper_limit="97.3"/>
                  <measurement group_id="O3" value="64.7" lower_limit="41.7" upper_limit="80.5"/>
                  <measurement group_id="O4" value="80.5" lower_limit="62.8" upper_limit="90.4"/>
                  <measurement group_id="O5" value="76.9" lower_limit="50.7" upper_limit="90.3"/>
                  <measurement group_id="O6" value="NA">The sample size was too small to suggest accurate estimates.</measurement>
                  <measurement group_id="O7" value="43.5" lower_limit="25.7" upper_limit="60.1"/>
                  <measurement group_id="O8" value="55.6" lower_limit="31.2" upper_limit="74.3"/>
                  <measurement group_id="O9" value="6.6" lower_limit="0.6" upper_limit="23.8"/>
                  <measurement group_id="O10" value="15.3" lower_limit="4.1" upper_limit="33.2"/>
                  <measurement group_id="O11" value="6.0" lower_limit="0.4" upper_limit="23.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate - Part 2</title>
        <description>OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death, censored at the participant's last contact date.</description>
        <time_frame>Baseline up to Year 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>All-treated population included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="45"/>
                  <measurement group_id="O8" value="31"/>
                  <measurement group_id="O9" value="35"/>
                  <measurement group_id="O10" value="29"/>
                  <measurement group_id="O11" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival (OS) Rate - Part 2</title>
            <description>OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death, censored at the participant's last contact date.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Year 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.9" lower_limit="92.0" upper_limit="97.9"/>
                  <measurement group_id="O2" value="98.8" lower_limit="92.0" upper_limit="99.8"/>
                  <measurement group_id="O3" value="82.8" lower_limit="65.6" upper_limit="91.9"/>
                  <measurement group_id="O4" value="93.9" lower_limit="82.3" upper_limit="98.0"/>
                  <measurement group_id="O5" value="96.3" lower_limit="76.5" upper_limit="99.5"/>
                  <measurement group_id="O6" value="NA">The sample size was too small to suggest accurate estimates.</measurement>
                  <measurement group_id="O7" value="77.6" lower_limit="62.3" upper_limit="87.3"/>
                  <measurement group_id="O8" value="73.8" lower_limit="54.4" upper_limit="86.0"/>
                  <measurement group_id="O9" value="45.7" lower_limit="28.4" upper_limit="61.4"/>
                  <measurement group_id="O10" value="41.4" lower_limit="23.7" upper_limit="58.3"/>
                  <measurement group_id="O11" value="16.7" lower_limit="5.2" upper_limit="33.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87.6" lower_limit="82.1" upper_limit="91.5"/>
                  <measurement group_id="O2" value="97.6" lower_limit="90.9" upper_limit="99.4"/>
                  <measurement group_id="O3" value="75.2" lower_limit="56.1" upper_limit="86.9"/>
                  <measurement group_id="O4" value="85.4" lower_limit="71.7" upper_limit="92.8"/>
                  <measurement group_id="O5" value="91.7" lower_limit="70.5" upper_limit="97.9"/>
                  <measurement group_id="O6" value="NA">The sample size was too small to suggest accurate estimates.</measurement>
                  <measurement group_id="O7" value="69.7" lower_limit="53.4" upper_limit="81.2"/>
                  <measurement group_id="O8" value="60.2" lower_limit="40.6" upper_limit="75.1"/>
                  <measurement group_id="O9" value="42.4" lower_limit="25.5" upper_limit="58.4"/>
                  <measurement group_id="O10" value="27.6" lower_limit="13.1" upper_limit="44.3"/>
                  <measurement group_id="O11" value="8.3" lower_limit="1.4" upper_limit="23.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Hematologic Response (CHR) in Advanced Leukemia Population - Part 2</title>
        <description>Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
        <time_frame>Baseline, Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Hematologic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline hematologic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="27"/>
                  <measurement group_id="O5" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Complete Hematologic Response (CHR) in Advanced Leukemia Population - Part 2</title>
            <description>Hematologic response was considered to be achieved if participants met all of the following criteria of CHR: White Blood Cells =&lt; institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes &lt;5% in blood, absolute neutrophil count &gt;= 1.0*10^9 per liter (/L), platelets &gt;=100*10^9/L but &lt;450*10^9/L, &lt;20% basophils in blood and no extramedulary involvement (including hepato- or splenomegaly), =&lt;5% BM blasts.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41.0" lower_limit="25.6" upper_limit="57.9"/>
                  <measurement group_id="O2" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                  <measurement group_id="O3" value="24.2" lower_limit="11.1" upper_limit="42.3"/>
                  <measurement group_id="O4" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                  <measurement group_id="O5" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2</title>
        <description>OHR included CHR, no evidence of leukemia (NEL), minor hematologic response (MiHR) or return to chronic phase (RCP), participants had to meet at least 1 of this criterion. Criteria for RCP: disappearance of features defining AP/BP, but still in CP and persistence of clonal evolution. Criteria for MiHR: &lt;15% blasts in blood and BM, &lt;30% blasts+promyelocytes in blood and BM, &lt;20% basophils in blood, no extramedullary disease other than liver/spleen. Criteria for CHR and NEL: &lt;20% basophils in blood, no extramedullary involvement including liver/spleen, no peripheral blasts or promyelocytes, myelocytes + metamyelocytes &lt;5% in blood, &lt;5% (NEL) and &lt;=5% (CHR) marrow blasts, 0.5*10^9 &lt;= Absolute neutrophil count (ANC) &lt;1.0*10^9/L (NEL) and ANC&gt;=1.0*10^9/L (CHR), 20*10^9 &lt;=platelets&lt;100 *10^9/L (NEL) and platelets&gt;=100 but &lt;450x10^9/L (CHR), white blood cells &lt;=institutional upper limit of the normal range.</description>
        <time_frame>Week 48</time_frame>
        <safety_issue>No</safety_issue>
        <population>Hematologic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline hematologic assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="27"/>
                  <measurement group_id="O5" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2</title>
            <description>OHR included CHR, no evidence of leukemia (NEL), minor hematologic response (MiHR) or return to chronic phase (RCP), participants had to meet at least 1 of this criterion. Criteria for RCP: disappearance of features defining AP/BP, but still in CP and persistence of clonal evolution. Criteria for MiHR: &lt;15% blasts in blood and BM, &lt;30% blasts+promyelocytes in blood and BM, &lt;20% basophils in blood, no extramedullary disease other than liver/spleen. Criteria for CHR and NEL: &lt;20% basophils in blood, no extramedullary involvement including liver/spleen, no peripheral blasts or promyelocytes, myelocytes + metamyelocytes &lt;5% in blood, &lt;5% (NEL) and &lt;=5% (CHR) marrow blasts, 0.5*10^9 &lt;= Absolute neutrophil count (ANC) &lt;1.0*10^9/L (NEL) and ANC&gt;=1.0*10^9/L (CHR), 20*10^9 &lt;=platelets&lt;100 *10^9/L (NEL) and platelets&gt;=100 but &lt;450x10^9/L (CHR), white blood cells &lt;=institutional upper limit of the normal range.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64.1" lower_limit="47.2" upper_limit="78.8"/>
                  <measurement group_id="O2" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                  <measurement group_id="O3" value="36.4" lower_limit="20.4" upper_limit="54.9"/>
                  <measurement group_id="O4" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                  <measurement group_id="O5" value="4.6" lower_limit="0.1" upper_limit="22.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="45"/>
                  <measurement group_id="O8" value="31"/>
                  <measurement group_id="O9" value="35"/>
                  <measurement group_id="O10" value="29"/>
                  <measurement group_id="O11" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
            <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.5"/>
                  <measurement group_id="O2" value="100.0"/>
                  <measurement group_id="O3" value="100.0"/>
                  <measurement group_id="O4" value="100.0"/>
                  <measurement group_id="O5" value="100.0"/>
                  <measurement group_id="O6" value="100.0"/>
                  <measurement group_id="O7" value="100.0"/>
                  <measurement group_id="O8" value="100.0"/>
                  <measurement group_id="O9" value="97.1"/>
                  <measurement group_id="O10" value="100.0"/>
                  <measurement group_id="O11" value="95.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.0"/>
                  <measurement group_id="O2" value="37.5"/>
                  <measurement group_id="O3" value="24.3"/>
                  <measurement group_id="O4" value="42.0"/>
                  <measurement group_id="O5" value="14.8"/>
                  <measurement group_id="O6" value="25.0"/>
                  <measurement group_id="O7" value="51.1"/>
                  <measurement group_id="O8" value="58.1"/>
                  <measurement group_id="O9" value="51.4"/>
                  <measurement group_id="O10" value="58.6"/>
                  <measurement group_id="O11" value="66.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Potentially Clinically Important (PCI) Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. PCI-AEs included hepatotoxicity, gastrointestinal toxicity: diarrhea, nausea, vomiting, hypersensitivity reactions, rash, edema, effusion, myelosuppression, hemorrhage, infection, cardiac events. Duration of AE was calculated as (stop date minus start date) plus 1 for non-missing and non-partial dates.</description>
        <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="76"/>
                  <measurement group_id="O8" value="64"/>
                  <measurement group_id="O9" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Potentially Clinically Important (PCI) Adverse Events (AEs)</title>
            <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. PCI-AEs included hepatotoxicity, gastrointestinal toxicity: diarrhea, nausea, vomiting, hypersensitivity reactions, rash, edema, effusion, myelosuppression, hemorrhage, infection, cardiac events. Duration of AE was calculated as (stop date minus start date) plus 1 for non-missing and non-partial dates.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Hepatotoxicity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108.0" lower_limit="3" upper_limit="595"/>
                  <measurement group_id="O2" value="85.0" lower_limit="1" upper_limit="363"/>
                  <measurement group_id="O3" value="20.0" lower_limit="14" upper_limit="84"/>
                  <measurement group_id="O4" value="25.0" lower_limit="9" upper_limit="171"/>
                  <measurement group_id="O5" value="65.0" lower_limit="8" upper_limit="176"/>
                  <measurement group_id="O6" value="8.0" lower_limit="8" upper_limit="8"/>
                  <measurement group_id="O7" value="47.0" lower_limit="6" upper_limit="413"/>
                  <measurement group_id="O8" value="15.5" lower_limit="1" upper_limit="46"/>
                  <measurement group_id="O9" value="5.0" lower_limit="1" upper_limit="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" lower_limit="1" upper_limit="786"/>
                  <measurement group_id="O2" value="21.5" lower_limit="1" upper_limit="764"/>
                  <measurement group_id="O3" value="14.0" lower_limit="1" upper_limit="368"/>
                  <measurement group_id="O4" value="28.5" lower_limit="1" upper_limit="589"/>
                  <measurement group_id="O5" value="15.0" lower_limit="1" upper_limit="761"/>
                  <measurement group_id="O6" value="3.0" lower_limit="2" upper_limit="28"/>
                  <measurement group_id="O7" value="19.0" lower_limit="1" upper_limit="947"/>
                  <measurement group_id="O8" value="16.0" lower_limit="1" upper_limit="211"/>
                  <measurement group_id="O9" value="11.0" lower_limit="1" upper_limit="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5" lower_limit="1" upper_limit="284"/>
                  <measurement group_id="O2" value="15.0" lower_limit="1" upper_limit="446"/>
                  <measurement group_id="O3" value="21.0" lower_limit="1" upper_limit="155"/>
                  <measurement group_id="O4" value="25.0" lower_limit="1" upper_limit="229"/>
                  <measurement group_id="O5" value="14.0" lower_limit="1" upper_limit="51"/>
                  <measurement group_id="O6" value="4.0" lower_limit="1" upper_limit="7"/>
                  <measurement group_id="O7" value="14.0" lower_limit="1" upper_limit="592"/>
                  <measurement group_id="O8" value="12.0" lower_limit="2" upper_limit="274"/>
                  <measurement group_id="O9" value="9.0" lower_limit="1" upper_limit="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.0" lower_limit="1" upper_limit="170"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="126"/>
                  <measurement group_id="O3" value="4.0" lower_limit="1" upper_limit="141"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1" upper_limit="77"/>
                  <measurement group_id="O5" value="8.5" lower_limit="3" upper_limit="25"/>
                  <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O7" value="5.5" lower_limit="1" upper_limit="142"/>
                  <measurement group_id="O8" value="5.0" lower_limit="1" upper_limit="55"/>
                  <measurement group_id="O9" value="3.0" lower_limit="1" upper_limit="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypersensitivity Reactions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.0" lower_limit="8" upper_limit="135"/>
                  <measurement group_id="O2" value="18.0" lower_limit="7" upper_limit="111"/>
                  <measurement group_id="O3" value="10.0" lower_limit="1" upper_limit="34"/>
                  <measurement group_id="O4" value="1.0" lower_limit="1" upper_limit="25"/>
                  <measurement group_id="O5" value="17.0" lower_limit="1" upper_limit="50"/>
                  <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O7" value="2.0" lower_limit="1" upper_limit="52"/>
                  <measurement group_id="O8" value="11.5" lower_limit="5" upper_limit="18"/>
                  <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.0" lower_limit="1" upper_limit="961"/>
                  <measurement group_id="O2" value="28.0" lower_limit="1" upper_limit="840"/>
                  <measurement group_id="O3" value="34.0" lower_limit="5" upper_limit="84"/>
                  <measurement group_id="O4" value="21.0" lower_limit="1" upper_limit="363"/>
                  <measurement group_id="O5" value="44.0" lower_limit="6" upper_limit="82"/>
                  <measurement group_id="O6" value="62.0" lower_limit="62" upper_limit="62"/>
                  <measurement group_id="O7" value="32.0" lower_limit="1" upper_limit="507"/>
                  <measurement group_id="O8" value="16.0" lower_limit="1" upper_limit="218"/>
                  <measurement group_id="O9" value="16.5" lower_limit="1" upper_limit="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.0" lower_limit="1" upper_limit="819"/>
                  <measurement group_id="O2" value="67.5" lower_limit="1" upper_limit="559"/>
                  <measurement group_id="O3" value="9.0" lower_limit="1" upper_limit="15"/>
                  <measurement group_id="O4" value="15.0" lower_limit="2" upper_limit="107"/>
                  <measurement group_id="O5" value="17.0" lower_limit="3" upper_limit="76"/>
                  <measurement group_id="O6" value="52.0" lower_limit="52" upper_limit="52"/>
                  <measurement group_id="O7" value="59.0" lower_limit="4" upper_limit="808"/>
                  <measurement group_id="O8" value="19.0" lower_limit="3" upper_limit="236"/>
                  <measurement group_id="O9" value="4.0" lower_limit="1" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Effusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.0" lower_limit="1" upper_limit="70"/>
                  <measurement group_id="O2" value="64.0" lower_limit="42" upper_limit="86"/>
                  <measurement group_id="O3" value="81.0" lower_limit="29" upper_limit="133"/>
                  <measurement group_id="O4" value="108.0" lower_limit="3" upper_limit="169"/>
                  <measurement group_id="O5" value="45.0" lower_limit="45" upper_limit="45"/>
                  <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O7" value="36.0" lower_limit="11" upper_limit="385"/>
                  <measurement group_id="O8" value="13.0" lower_limit="13" upper_limit="13"/>
                  <measurement group_id="O9" value="34.0" lower_limit="34" upper_limit="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myelosuppression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114.0" lower_limit="7" upper_limit="659"/>
                  <measurement group_id="O2" value="84.0" lower_limit="13" upper_limit="833"/>
                  <measurement group_id="O3" value="44.0" lower_limit="4" upper_limit="197"/>
                  <measurement group_id="O4" value="105.0" lower_limit="7" upper_limit="787"/>
                  <measurement group_id="O5" value="67.5" lower_limit="14" upper_limit="384"/>
                  <measurement group_id="O6" value="69.0" lower_limit="14" upper_limit="124"/>
                  <measurement group_id="O7" value="65.5" lower_limit="1" upper_limit="1009"/>
                  <measurement group_id="O8" value="39.0" lower_limit="1" upper_limit="322"/>
                  <measurement group_id="O9" value="8.0" lower_limit="1" upper_limit="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.5" lower_limit="1" upper_limit="160"/>
                  <measurement group_id="O2" value="6.0" lower_limit="2" upper_limit="54"/>
                  <measurement group_id="O3" value="8.0" lower_limit="2" upper_limit="14"/>
                  <measurement group_id="O4" value="1.0" lower_limit="1" upper_limit="1"/>
                  <measurement group_id="O5" value="8.0" lower_limit="5" upper_limit="132"/>
                  <measurement group_id="O6" value="23.0" lower_limit="23" upper_limit="23"/>
                  <measurement group_id="O7" value="18.0" lower_limit="2" upper_limit="237"/>
                  <measurement group_id="O8" value="10.0" lower_limit="1" upper_limit="43"/>
                  <measurement group_id="O9" value="2.0" lower_limit="1" upper_limit="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.5" lower_limit="3" upper_limit="416"/>
                  <measurement group_id="O2" value="22.0" lower_limit="3" upper_limit="92"/>
                  <measurement group_id="O3" value="17.5" lower_limit="1" upper_limit="49"/>
                  <measurement group_id="O4" value="13.0" lower_limit="4" upper_limit="366"/>
                  <measurement group_id="O5" value="14.5" lower_limit="1" upper_limit="29"/>
                  <measurement group_id="O6" value="13.0" lower_limit="12" upper_limit="67"/>
                  <measurement group_id="O7" value="20.0" lower_limit="1" upper_limit="1052"/>
                  <measurement group_id="O8" value="14.0" lower_limit="1" upper_limit="78"/>
                  <measurement group_id="O9" value="8.0" lower_limit="1" upper_limit="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiac Events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.0" lower_limit="1" upper_limit="607"/>
                  <measurement group_id="O2" value="15.0" lower_limit="1" upper_limit="84"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1" upper_limit="1"/>
                  <measurement group_id="O4" value="32.5" lower_limit="1" upper_limit="169"/>
                  <measurement group_id="O5" value="1.0" lower_limit="1" upper_limit="1"/>
                  <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                  <measurement group_id="O7" value="5.5" lower_limit="1" upper_limit="1006"/>
                  <measurement group_id="O8" value="4.0" lower_limit="1" upper_limit="43"/>
                  <measurement group_id="O9" value="1.0" lower_limit="1" upper_limit="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Laboratory Tests Results</title>
        <description>Laboratory values included urinalysis, complete blood count (CBC), prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), blood chemistry and serum pregnancy test (Î²-HCG). Potentially clinically important (PCI) changes in laboratory assessments were reported. Any laboratory value that was identified as clinically significant was reported as an AE. PCI laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.</description>
        <time_frame>Week 1, 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="76"/>
                  <measurement group_id="O8" value="64"/>
                  <measurement group_id="O9" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Change From Baseline in Laboratory Tests Results</title>
            <description>Laboratory values included urinalysis, complete blood count (CBC), prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), blood chemistry and serum pregnancy test (Î²-HCG). Potentially clinically important (PCI) changes in laboratory assessments were reported. Any laboratory value that was identified as clinically significant was reported as an AE. PCI laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="7"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="33"/>
                  <measurement group_id="O8" value="9"/>
                  <measurement group_id="O9" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="11"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="24"/>
                  <measurement group_id="O8" value="41"/>
                  <measurement group_id="O9" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</title>
        <description>Criteria for PCI changes in ECG (12-lead) were defined as: no sinus rhythm; PR interval &gt;=220 msec and increase of &gt;=20 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) &gt;500 msec or increase of &gt;60 msec; heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
        <time_frame>Baseline, 0 (pre-dose), 2, 4, 6 hours on Day 1, 0 (pre-dose), 2, 4, 6, 20-23 hours on Day 21, and end of treatment visit</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication. 'N' (Number of Participants Analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="74"/>
                  <measurement group_id="O8" value="63"/>
                  <measurement group_id="O9" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</title>
            <description>Criteria for PCI changes in ECG (12-lead) were defined as: no sinus rhythm; PR interval &gt;=220 msec and increase of &gt;=20 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) &gt;500 msec or increase of &gt;60 msec; heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="28"/>
                  <measurement group_id="O8" value="35"/>
                  <measurement group_id="O9" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Findings of Chest X-ray</title>
        <time_frame>Baseline, Week 8, and end of treatment</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Data for this outcome measure was not statistically summarized for analysis, but collected and reported in individual participant listings as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Change From Baseline in Findings of Chest X-ray</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5"/>
                  <measurement group_id="O6"/>
                  <measurement group_id="O7"/>
                  <measurement group_id="O8"/>
                  <measurement group_id="O9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Concomitant Medications for Management of Adverse Events (AEs)</title>
        <description>Number of participants taking any non-study medications which were administered from Study Day 1 to 30 days after last dose of study treatment as a management of an AE are reported.</description>
        <time_frame>Baseline up to end of treatment (Year 5)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="76"/>
                  <measurement group_id="O8" value="64"/>
                  <measurement group_id="O9" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Received Concomitant Medications for Management of Adverse Events (AEs)</title>
            <description>Number of participants taking any non-study medications which were administered from Study Day 1 to 30 days after last dose of study treatment as a management of an AE are reported.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hepatotoxicity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="3"/>
                  <measurement group_id="O8" value="2"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="27"/>
                  <measurement group_id="O5" value="16"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="40"/>
                  <measurement group_id="O8" value="23"/>
                  <measurement group_id="O9" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="8"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="17"/>
                  <measurement group_id="O8" value="22"/>
                  <measurement group_id="O9" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Toxicity - Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="4"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="16"/>
                  <measurement group_id="O8" value="14"/>
                  <measurement group_id="O9" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypersensitivity Reactions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="3"/>
                  <measurement group_id="O8" value="3"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="20"/>
                  <measurement group_id="O8" value="10"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="5"/>
                  <measurement group_id="O8" value="7"/>
                  <measurement group_id="O9" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Effusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="6"/>
                  <measurement group_id="O8" value="2"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myelosuppression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="2"/>
                  <measurement group_id="O7" value="13"/>
                  <measurement group_id="O8" value="9"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="3"/>
                  <measurement group_id="O8" value="6"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="16"/>
                  <measurement group_id="O5" value="8"/>
                  <measurement group_id="O6" value="3"/>
                  <measurement group_id="O7" value="32"/>
                  <measurement group_id="O8" value="29"/>
                  <measurement group_id="O9" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiac Events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="5"/>
                  <measurement group_id="O8" value="2"/>
                  <measurement group_id="O9" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group Performance Status (ECOG-PS)</title>
        <description>ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.</description>
        <time_frame>Baseline, Week 1, 2, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks up to Year 5</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O7">
            <title>Bosutinib 500 mg, AP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O8">
            <title>Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with advanced phase (AP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, BP-CML IM R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) imatinib (IM) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O10">
            <title>Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with blast phase (BP) Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I) chronic myelogenous leukemia (CML) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
          <group group_id="O11">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) until disease progression, unacceptable toxicity, or withdrawal of consent occurred.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="27"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="45"/>
                  <measurement group_id="O8" value="31"/>
                  <measurement group_id="O9" value="35"/>
                  <measurement group_id="O10" value="29"/>
                  <measurement group_id="O11" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group Performance Status (ECOG-PS)</title>
            <description>ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Grade 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="21"/>
                  <measurement group_id="O5" value="19"/>
                  <measurement group_id="O6" value="2"/>
                  <measurement group_id="O7" value="14"/>
                  <measurement group_id="O8" value="9"/>
                  <measurement group_id="O9" value="9"/>
                  <measurement group_id="O10" value="2"/>
                  <measurement group_id="O11" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Grade 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="10"/>
                  <measurement group_id="O8" value="5"/>
                  <measurement group_id="O9" value="7"/>
                  <measurement group_id="O10" value="2"/>
                  <measurement group_id="O11" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Grade 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="1"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="0"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="0"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Grade 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="1"/>
                  <measurement group_id="O9" value="2"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Grade 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="14"/>
                  <measurement group_id="O8" value="8"/>
                  <measurement group_id="O9" value="7"/>
                  <measurement group_id="O10" value="7"/>
                  <measurement group_id="O11" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Grade 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="1"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="5"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="5"/>
                  <measurement group_id="O11" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="2"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="2"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="1"/>
                  <measurement group_id="O9" value="1"/>
                  <measurement group_id="O10" value="0"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 2, End of Treatment: Grade 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="1"/>
                  <measurement group_id="O10" value="0"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 2, End of Treatment: Grade 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 2, End of Treatment: Grade 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="7"/>
                  <measurement group_id="O10" value="2"/>
                  <measurement group_id="O11" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 2, End of Treatment: Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="1"/>
                  <measurement group_id="O9" value="1"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 2, End of Treatment: Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="0"/>
                  <measurement group_id="O11" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 0, End of Treatment: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Grade 1, End of Treatment: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                  <measurement group_id="O10" value="3"/>
                  <measurement group_id="O11" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Physical Examinations and Vital Signs</title>
        <description>Number of participants with PCI physical examinations and vital signs is reported during therapy and at post therapy. Criteria for PCI change in vital signs: heart rate value of &lt;40 beats per minute and value &gt;150 beats per minute, systolic blood pressure (SBP) of &lt;80 or &gt;210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of &lt;40 or &gt;130 mmHg, temperature &lt;32 or &gt;40 degree centigrade, respiratory rate of &lt;10 or &gt;50 breaths/minute and criteria for PCI change in physical examination: &gt;=10% increase or decrease of body weight (Wt) in kilogram (kg).</description>
        <time_frame>Baseline up to end of treatment (Year 5)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population included all participants who receive at least one dose of study medication. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosutinib 500 mg, CP2L-CML IM-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) resistant/refractory (R) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase sarcoma (Src), abelson kinase (Abl), or Src-Abl inhibitor exposure other than IM.</description>
          </group>
          <group group_id="O2">
            <title>Bosutinib 500 mg, CP2L-CML IM-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase second-line (CP2L) imatinib (IM) intolerant (I) chronic myelogenous leukemia (CML); who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.</description>
          </group>
          <group group_id="O3">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R) chronic myelogenous leukemia (CML).</description>
          </group>
          <group group_id="O4">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) intolerant (I) chronic myelogenous leukemia (CML).</description>
          </group>
          <group group_id="O5">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) resistant (R) chronic myelogenous leukemia (CML).</description>
          </group>
          <group group_id="O6">
            <title>Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with chronic phase third-line (CP3L) imatinib (IM) resistant/intolerant (R/I), dasatinib (D) and nilotinib (NI) resistant/intolerant (R/I) or imatinib (IM) resistant/intolerant (R/I) and nilotinib (NI) intolerant (I) chronic myelogenous leukemia (CML).</description>
          </group>
          <group group_id="O7">
            <title>AP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in advanced phase (AP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I).</description>
          </group>
          <group group_id="O8">
            <title>BP-CML Total</title>
            <description>All participants who received bosutinib 500 mg orally once daily in blast phase (BP) chronic myelogenous leukemia (CML) who were imatinib (IM) resistant/intolerant (R/I) or Multi-TKI (multiple tyrosine kinase inhibitor: imatinib, dasatinib and/or nilotinib) resistant/intolerant (R/I).</description>
          </group>
          <group group_id="O9">
            <title>Bosutinib 500 mg, Ph+ ALL (Part 2)</title>
            <description>Bosutinib 500 mg was administered orally once-daily in participants with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="45"/>
                  <measurement group_id="O5" value="26"/>
                  <measurement group_id="O6" value="4"/>
                  <measurement group_id="O7" value="72"/>
                  <measurement group_id="O8" value="57"/>
                  <measurement group_id="O9" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Change From Baseline in Physical Examinations and Vital Signs</title>
            <description>Number of participants with PCI physical examinations and vital signs is reported during therapy and at post therapy. Criteria for PCI change in vital signs: heart rate value of &lt;40 beats per minute and value &gt;150 beats per minute, systolic blood pressure (SBP) of &lt;80 or &gt;210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of &lt;40 or &gt;130 mmHg, temperature &lt;32 or &gt;40 degree centigrade, respiratory rate of &lt;10 or &gt;50 breaths/minute and criteria for PCI change in physical examination: &gt;=10% increase or decrease of body weight (Wt) in kilogram (kg).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>On Therapy SBP: &gt;210 mmHg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>On Therapy Wt: Increase of &gt;=10% from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="7"/>
                  <measurement group_id="O8" value="5"/>
                  <measurement group_id="O9" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>On Therapy Wt: Decrease of &gt;=10% from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="16"/>
                  <measurement group_id="O8" value="5"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>On Therapy Respiratory Rate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>On Therapy Temperature: &gt;40 degree centigrade</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post Therapy SBP: &gt;210 mmHg:</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post Therapy Wt: Increase of &gt;=10% from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="NA">None of the participant was assessed.</measurement>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post Therapy Wt: Decrease of &gt;=10% from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="1"/>
                  <measurement group_id="O8" value="0"/>
                  <measurement group_id="O9" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP2L-CML</title>
          <description>All participants who received bosutinib 500 mg orally once daily for 48 weeks in chronic phase second-line (CP2L) chronic myelogenous leukemia (CML), who were imatinib (IM) resistant/refractory (R) and IM intolerant (I).</description>
        </group>
        <group group_id="E2">
          <title>CP3L-CML</title>
          <description>All participants who received bosutinib 500 mg orally once daily for 48 weeks in chronic phase third-line (CP3L) chronic myelogenous leukemia (CML), participants were imatinib (IM) resistant/intolerant (R/I) and dasatinib (D) resistant (R), dasatinib (D) intolerant (I), nilotinib (NI) resistant (R), and dasatinib and nilotinib resistant/intolerant (R/I) or nilotinib intolerant (I).</description>
        </group>
        <group group_id="E3">
          <title>Advanced Phase</title>
          <description>All participants who received bosutinib 500 mg orally once daily for 48 weeks in advanced phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Proctocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Saliva altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Blast cell crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blast crisis in myelogenous leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukaemic infiltration brain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukaemic infiltration extramedullary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukostasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tumour rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Encephalitis post varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Circumoral oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Micrographic skin surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses of progression free survival and overall survival was based on all-treated population, instead of evaluable population which was the primary efficacy population as per planned analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
